A. J. Garber - Concepedia

Author

A. J. Garber

Baylor College of Medicine

Also Known As

A Garber, A J Garber, A. Garber, A. J. Garber, A. Sämann, A.J. Garber, Alan J. Garber, Am. Garber, Garber, A

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Baylor College of Medicine Methodist Hospital Novo Nordisk (Denmark)Novo Nordisk (United States)Washington University in St. Louis

About

A. J. Garber is an author at Baylor College of Medicine specializing in medicine, metabolism, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	881
2	Health Sciences	9	9	647
3	Anesthesia	2	2	219
4	Natural Sciences	1	1	35
5	Public Health	1	1	34

A. J. Garber

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. A. J. Garber, Philip E. Cryer, Julio V. Santiago, Journal of Clinical Investigation	1976	354
Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Johan Jendle, Michael A. Nauck, David R. Matthews, Diabetes Obesity and Metabolism	2009	295
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study* A. J. Garber, Anja Schweizer, Michelle A. Baron, Diabetes Obesity and Metabolism	2006	268
Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study) A. J. Garber, Jack Wahlen, Tyler S. Wahl, Diabetes Obesity and Metabolism	2005	261
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Richard E. Pratley, Michael A. Nauck, Timothy S. Bailey, International Journal of Clinical Practice	2011	248
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea* A. J. Garber, James E. Foley, Mary Ann Banerji, Diabetes Obesity and Metabolism	2008	232
Hepatic Ketogenesis and Gluconeogenesis in Humans A. J. Garber, P. H. Menzel, G. Boden, Journal of Clinical Investigation Metabolic DisorderFatty Liver DiseaseKetone-body RemovalMetabolic SyndromeBody Composition	1974	221
Alanine and glutamine synthesis and release from skeletal muscle. I. Glycolysis and amino acid release. A. J. Garber, Irene E. Karl, David Kipnis Journal of Biological Chemistry	1976	208
Alanine and glutamine synthesis and release from skeletal muscle. II. The precursor role of amino acids in alanine and glutamine synthesis. A. J. Garber, Irene E. Karl, David Kipnis Journal of Biological Chemistry Animal PhysiologyMuscle PhysiologyBiosynthesisAnesthesiaAmino Acids	1976	200
Liraglutide, a once‐daily human glucagon‐like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes A. J. Garber, Robert R. Henry, Robert E. Ratner, Diabetes Obesity and Metabolism	2010	194

Page 1